---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-014287"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T02:59:56.608700+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Rezolute Q2 net loss $22.8M; Phase 3 congenital HI study misses primary endpoint

## Summary
- Net loss $22.8M vs $15.7M YoY; R&D $14.3M, G&A $9.9M; cash $132.9M down from $167.9M.
- Phase 3 sunRIZE study of ersodetug for congenital HI did not meet primary or key secondary endpoints.
- Reduction in hypoglycemia by CGM was statistically significant at Week 16 but not at Week 24 endpoint.
- FDA meeting planned under Breakthrough Therapy designation before end of Q1 to discuss next steps.
- Enrollment ongoing for tumor HI Phase 3 upLIFT study; topline results expected H2 2026.

## SEC filing metadata
- accession: 0001104659-26-014287
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465926014287/0001104659-26-014287-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465926014287/tm265567d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-014287
- JSON: https://secwatch.observer/filing/0001104659-26-014287.json
- Plain text: https://secwatch.observer/filing/0001104659-26-014287.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.